Recent Considerations in the Application of RAPTA‐C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies
The organometallic ruthenium(II) [Ru(arene)Cl2PTA] PTA ‐ 1,3,5‐triaza‐7‐phosphaadamantane compound, RAPTA‐C, represents an innovative anti‐cancer therapeutic and a better‐tolerated alternative to platinum (Pt)‐based chemotherapeutic drugs in the treatment of cancer. RAPTA‐C exhibits anti‐metastatic, anti‐angiogenic, and anti‐tumoral activities through protein and histone–deoxyribonucleic acid alterations. In comparison to other ruthenium‐based drugs, which have been recently evaluated in clinical trials, RAPTA‐C is strikingly competitive, especially when administered in combination with other targeted drugs. In this review, the uniqueness of RAPTA‐C as an anti‐cancer chemotherapeutic compared to metal‐based drugs under clinical evaluation and those approved by the Food and Drug Administration is emphasized; specifically, comparing the application of RAPTA‐C to platinum‐based drugs, for example, cisplatin and oxaliplatin, as well as to prominent ruthenium‐based compounds, such as NAMI‐A imidazolium‐trans‐tetrachloro(dimethylsulfoxide) imidazoleruthenium(III) and trans‐[tetrachlorobis (1Hindazole) ruthenate(III)] (KP1019)/(N)KP1339 (N)KP1339 ‐ sodium. Additionally, the possible correlation between RAPTA‐C and immune response modulation, as well as potential applications of RAPTA‐C in combination with immune therapeutic regimens, is highlighted.
Top-30
Journals
|
1
2
3
4
5
6
7
8
|
|
|
Inorganic Chemistry
8 publications, 10.53%
|
|
|
Coordination Chemistry Reviews
7 publications, 9.21%
|
|
|
Journal of Medicinal Chemistry
5 publications, 6.58%
|
|
|
Applied Organometallic Chemistry
4 publications, 5.26%
|
|
|
Dalton Transactions
4 publications, 5.26%
|
|
|
Pharmaceuticals
3 publications, 3.95%
|
|
|
Molecules
3 publications, 3.95%
|
|
|
Inorganica Chimica Acta
3 publications, 3.95%
|
|
|
ChemMedChem
3 publications, 3.95%
|
|
|
Pharmaceutics
2 publications, 2.63%
|
|
|
European Journal of Medicinal Chemistry
2 publications, 2.63%
|
|
|
Polyhedron
2 publications, 2.63%
|
|
|
Chemistry - A European Journal
2 publications, 2.63%
|
|
|
Journal of Materials Chemistry B
2 publications, 2.63%
|
|
|
New Journal of Chemistry
2 publications, 2.63%
|
|
|
Journal of Inorganic Biochemistry
2 publications, 2.63%
|
|
|
Angewandte Chemie - International Edition
1 publication, 1.32%
|
|
|
Journal of Physical Chemistry C
1 publication, 1.32%
|
|
|
Molecular Pharmaceutics
1 publication, 1.32%
|
|
|
Cancers
1 publication, 1.32%
|
|
|
Journal of Biological Inorganic Chemistry
1 publication, 1.32%
|
|
|
Biomaterials Advances
1 publication, 1.32%
|
|
|
Current Opinion in Chemical Biology
1 publication, 1.32%
|
|
|
Chemico-Biological Interactions
1 publication, 1.32%
|
|
|
ChemBioChem
1 publication, 1.32%
|
|
|
Chemical Record
1 publication, 1.32%
|
|
|
Angewandte Chemie
1 publication, 1.32%
|
|
|
Photochemistry and Photobiology
1 publication, 1.32%
|
|
|
Chemistry and Biodiversity
1 publication, 1.32%
|
|
|
ACS Omega
1 publication, 1.32%
|
|
|
1
2
3
4
5
6
7
8
|
Publishers
|
2
4
6
8
10
12
14
16
18
20
|
|
|
Elsevier
19 publications, 25%
|
|
|
American Chemical Society (ACS)
17 publications, 22.37%
|
|
|
Wiley
16 publications, 21.05%
|
|
|
Royal Society of Chemistry (RSC)
11 publications, 14.47%
|
|
|
MDPI
10 publications, 13.16%
|
|
|
Springer Nature
1 publication, 1.32%
|
|
|
Taylor & Francis
1 publication, 1.32%
|
|
|
Hindawi Limited
1 publication, 1.32%
|
|
|
2
4
6
8
10
12
14
16
18
20
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.